Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9752W HIGH $2.62
Volume
1.70 M
Value Traded
1.26 M
Short % Float
19.8%
-4.46%Week
-19.55%1 Month
-27.21%3 Month
-37.43%6 Month
-88.32%5 Year
-87.37%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
165.32 M
EPS (TTM)
-0.86
P/E Ratio
-
Ent. Value
60.01 M
Total Shares
154.46 M
Float Shares
115.42 M
Insiders
25.30%
Institutions
34.36%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CHRS Catalyst Timeline
Dated clinical, regulatory and corporate events for Coherus Oncology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Coherus Oncology, Inc.
738Total events
5Upcoming
238Tier-1 (high impact)
2014 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Timing GuidancePresentation
Coherus initiates process to market and sell Legacy BioSim Assets, retaining Oppenheimer as financial advisor
▲Partnership / LicenseCorporate
Coherus retains Oppenheimer & Co. to market and sell Legacy BioSim Assets
●Timing GuidancePresentation
Declaration of special dividend of contingent value rights (CVRs)
▲Enrollment CompleteCasdozokitugTrial
Enrollment complete in Phase 2 trial of casdozokitug in 1L uHCC
unresectable hepatocellular carcinoma (uHCC)source ↗
▲Enrollment CompletetagmokitugTrial
Phase 1b/2a study of tagmokitug in 4L+ CRC fully enrolled
colorectal cancer (CRC)source ↗
●Trial InitiationpasritamigTrial
Anticipate initiating pasritamig combination study in mCRPC in the fall
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Trial InitiationtagmokitugTrial
Phase 1b study of tagmokitug with pasritamig in mCRPC expected to initiate in fall 2026
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Topline ReadoutCasdozokitugClinical Data
Initial data from 1L HCC Phase 2 study expected around mid-year 2026
first-line unresectable hepatocellular carcinoma (uHCC)source ↗
▲Enrollment CompleteCasdozokitugTrial
Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for casdozokitug
first-line unresectable hepatocellular carcinoma (uHCC)source ↗
◆Quarterly UpdateCorporate
Full year and Q4 2025 financial results release and conference call
▼Equity OfferingCorporate
Closing of underwritten public offering of 28,600,000 shares at $1.75 per share
▼Equity OfferingCorporate
Pricing of underwritten public offering of 28,600,000 shares at $1.75 per share
◆Oral PresentationPresentation
Coherus management to present at 44th Annual J.P. Morgan Healthcare Conference
◆Topline ReadoutCasdozokitugClinical Data
First data readout expected from Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC
1L hepatocellular carcinoma (HCC)source ↗
◆Topline ReadoutCHS-114Clinical Data
Results from second-line Phase 1 dose optimization study in HNSCC and gastric cancer expected
head and neck squamous cell carcinoma and gastric cancersource ↗
▲Full ResultsLOQTORZIApprovedClinical Data
Six-year OS follow-up results from JUPITER-02 presented at ESMO Asia 2025
recurrent or metastatic nasopharyngeal carcinomasource ↗
●Oral PresentationLOQTORZIApprovedPresentation
Abstract #1279 presented at ESMO Asia 2025
recurrent or metastatic nasopharyngeal carcinomasource ↗
▲PublicationtagmokitugPresentation
Publication in Molecular Cancer Therapeutics highlighting pharmacology of tagmokitug
solid tumorssource ↗
◆Oral PresentationCHS-114Presentation
SITC 2025 presentation of multiomic biomarker data from CHS-114 Phase 1b dose expansion arm
head and neck squamous cell carcinomasource ↗
▲Interim AnalysisCHS-114Trial
Interim analysis from dose expansion phase shows CHS-114 depletes CCR8+ Tregs and increases CD8+ T cells
head and neck squamous cell carcinomasource ↗
◆Enrollment UpdateCHS-114Trial
Ongoing enrollment in dose optimization arm evaluating CHS-114 and toripalimab
head and neck squamous cell carcinomasource ↗
●Management ChangeCorporate
Arvind Sood appointed Chief Strategy and Corporate Affairs Officer
▲Trial InitiationCHS-114Trial
CHS-114 clinical program expanded to include colorectal cancer
colorectal cancersource ↗
◆Poster PresentationCHS-114Presentation
Poster presentation at SITC 2025 on CHS-114 anti-CCR8 antibody
advanced solid tumorssource ↗
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference presentation
▲Partnership / LicenseCorporate
Clinical collaboration with STORM Therapeutics to evaluate STC-15 in combination with LOQTORZI
▲First Patient DosedLOQTORZIApprovedTrial
First patient dosed in Phase 1b/2 study of LOQTORZI + STC-15
non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, endometrial cancersource ↗
●Equity OfferingCorporate
Expected repurchase of remaining approximately $60 million aggregate principal amount of 2026 Convertible Notes on May 15, 2025
●Enrollment UpdateCasdozokitugTrial
Enrollment ongoing in Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC
1L hepatocellular carcinoma (HCC)source ↗
◆Poster PresentationCHS-114Presentation
Poster presentation of interim data from Phase 1 dose expansion study of CHS-114 at AACR 2025
recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)source ↗
●Oral PresentationCHS-114Presentation
Investor and analyst call with study investigator Dr. Douglas Adkins
recurrent/metastatic head and neck squamous cell carcinomasource ↗
▲Runway Guidance UpdateCorporate
Cash runway extended over two years into 2027 with $250 million post-close balance
Past FDA Catalysts and PDUFA Decisions
How CHRS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | CHS-114 with toripalimab | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$67M
Pipeline Value
$51M
Commercial Value
Overvalued
Valuation Signal
6
Drugs Scored
0.6x
rNPV / MCap
Top 47%
Micro Cap(rank 311 of 660)
Percentile Rank
Coherus Oncology, Inc. faces pipeline headwinds (37/100), with $1.2B risk-adjusted pipeline value, led by Toripalimab in Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) (Phase 2), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $50.9M x 1.0 = $51M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| LOQTORZI | $49M | $31M | +59.6% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Toripalimab Monoclonal antibodyNCT07140679 | Localized Colon Carcinoma | Phase 2 | RECRUITING | 40 | Dec 31, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every CHRS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| tagmokitug | solid tumors | Phase 1b/2a | 2026-01-05 | picomolar affinity for CCR8; no off-target binding; selective reductions in CCR8+ TregsRead More | Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McMichael Bryan JOfficer (Chief Financial Officer) | Disposition | -100,000 | $0.00 | 05/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CHRS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 0.4 % (-33.3 %) | 4.80 M | 3.43 M |
CHRS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CHRS ranks across every disease it competes in
Competitive Position is a premium feature
See how CHRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCHRS News
CHRSCoherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Coherus Oncology has initiated the marketing of its legacy biosimilar assets, engaging Oppenheimer & Co. as its financial advisor. The company aims to attract bids for these assets, which include patents and royalties. Shareholders will receive contingent value rights (CVRs) tied to the proceeds from any sale or licensing agreements.
Read more →CHRSCoherus to Participate in Upcoming Investor Conferences
Coherus Oncology, Inc. has announced its participation in several upcoming investor conferences in New York. The events include the Baird 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference, both scheduled for September 15, 2026. The presentations will be available via webcast, and one-on-one meetings with management can be requested.
Read more →CHRS▲ +16.5%on this news
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology announced a special dividend of contingent value rights (CVRs) for stockholders, entitling them to net proceeds from the sale of its legacy biosimilar assets. This move marks a significant shift towards focusing on innovative oncology solutions. The CVRs will be distributed on October 7, 2026, to stockholders of record as of September 30, 2026.
Read more →CHRS▼ -12.8%on this news
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology reported a 15% increase in LOQTORZI revenue for Q2 2026, totaling $13.6 million. The company highlighted emerging clinical data for tagmokitug in head and neck cancer, with further data expected in October. Despite the revenue growth, Coherus continues to face significant net losses, although operational costs have decreased.
Read more →CHRSCoherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
Coherus Oncology will announce its second quarter 2026 financial results on August 5, 2026. A conference call will follow at 5:00 p.m. EDT, where management will discuss the results and provide a business update. The company is focused on growing sales of its PD-1 inhibitor, LOQTORZI, and advancing its clinical pipeline.
Read more →CHRSCoherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus Oncology and Zumutor Biologics have initiated a Phase 1 clinical study to evaluate ZM008, an anti-LLT1 monoclonal antibody, in combination with LOQTORZI, a next-generation PD-1 inhibitor. The first patient has been dosed, marking a significant step in the collaboration between the two companies. This study aims to assess the efficacy and safety of the combination treatment.
Read more →CHRS▲ +11.4%on this news
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology announced its financial results for Q1 2026, revealing a net revenue of $11.8 million from LOQTORZI. The company completed patient accrual for its first line hepatocellular carcinoma Phase 2 trial of casdozokitug. Coherus also highlighted updates on the developmental progress of tagmokitug, describing its safety and immune response benefits, while addressing ongoing financial losses and reduced R&D expenses.
Read more →CHRSCoherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Coherus Oncology, Inc. will release its first quarter 2026 financial results on May 11, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. Eastern Time to discuss the results and provide a business update. The company is focused on advancing its oncology pipeline, which includes several mid-stage clinical candidates.
Read more →CHRS▲ +6%on this news
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Coherus Oncology reported a significant increase in LOQTORZI sales for the full year 2025, with net revenues reaching $40.8 million. The company has effectively reduced its debt from $480 million to $38.8 million over the past two years. Despite revenue growth, Coherus continued to incur noteworthy net losses for both the fourth quarter and the entire year. The company remains focused on advancing its promising pipeline candidates with expected clinical data releases in 2026.
Read more →CHRSCoherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Coherus Oncology, Inc. will release its full year and fourth quarter 2025 financial results on March 9, 2026. Following the release, the management team will host a conference call and webcast to discuss the results and provide a business update. The company is focused on growing its oncology product sales and advancing its clinical pipeline.
Read more →CHRSCoherus Oncology to Participate in Upcoming Investor Conferences
Coherus Oncology announced its participation in upcoming investor conferences, where senior management will present. The presentations will be available via webcast, and replays will be accessible for 90 days. The company is focused on advancing its oncology pipeline, including LOQTORZI and other clinical candidates targeting various cancers.
Read more →CHRSCoherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
Coherus Oncology, Inc. has successfully closed a public offering of 28.6 million shares of common stock at $1.75 per share, raising approximately $50.1 million. The funds will be used to support the commercialization of LOQTORZI and further clinical development of its pipeline candidates. The offering was led by notable healthcare investors, reflecting confidence in Coherus's strategic direction.
Read more →CHRS▼ -19.9%on this newsshared move
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Coherus Oncology, Inc. has announced the pricing of a public offering consisting of 28,600,000 shares of its common stock at a price of $1.75 per share, aiming to raise approximately $50.1 million. The company plans to use the net proceeds to support the commercialization of its oncology drug LOQTORZI, advance clinical development of other candidates, and for general corporate purposes. The offering is expected to close on or about February 17, 2026, pending customary closing conditions. Coherus' recent activities reflect its strategy to enhance its oncology pipeline and drive future growth.
Read more →CHRSCoherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
Coherus Oncology, Inc. has announced a proposed underwritten public offering of its common stock to bolster the commercialization of its PD-1 inhibitor, LOQTORZI, among other uses. The offering includes an option for underwriters to purchase additional shares, and will be guided by TD Cowen, Guggenheim Securities, and Oppenheimer & Co. The company stresses that the offering is subject to market conditions and does not guarantee completion or specific terms.
Read more →CHRS▼ -5.6%on this news· ran to +17% by day 3
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Coherus Oncology, Inc. (NASDAQ: CHRS) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time. The event will feature a presentation by senior management and will be accessible via a webcast. Coherus specializes in oncology, offering an approved PD-1 inhibitor and developing additional candidates for various cancer indications. This initiative highlights the company's strategic efforts to increase its market presence and bolster its clinical pipeline.
Read more →CHRS▲ +5.1%on this newsshared move
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
Coherus Oncology announced the publication of research on its investigational antibody, tagmokitug, in Molecular Cancer Therapeutics. The study highlights its high selectivity and binding affinity for CCR8, demonstrating significant potential in targeting solid tumors. The findings support ongoing clinical trials evaluating tagmokitug's effectiveness in combination with toripalimab.
Read more →CHRSxA9;2026 Coherus Oncology, Inc. Coherus Oncology Value Proposition Shareholder Value Creation Focused on Drugs, Data and Deals 1 DRUGS DATA DEALS Tagmokitug anti-CCR8 cytolytic antibody Casdozokitug IL-27 antagonist Comm
Coherus Oncology, Inc. has reported promising preliminary financial data for the fourth quarter and full year of 2025. The company anticipated strong demand for its drug LOQTORZI, with projections indicating revenues could reach between $150-200 million by 2028. This revenue growth is supported by a projected quarter-over-quarter increase of 10-15% due to ongoing commercial efforts. The financial figures, however, are preliminary and subject to change as they have not yet been audited.
Read more →CHRS▲ +6.7%on this news· ran to +19% by day 3
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
Coherus Oncology has announced promising six-year follow-up results from its Phase 3 JUPITER-02 trial, indicating that the combination of LOQTORZI and chemotherapy significantly improves median overall survival in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). The study reports a median survival of 64.8 months for those receiving the combination therapy compared to 33.7 months for chemotherapy alone. These findings stress the need for integrating LOQTORZI as a first-line treatment option, suggesting it may transform patient outcomes in this aggressive cancer setting.
Read more →CHRS▼ -7.4%on this news
Cautionary Statement Regarding Forward-Looking Statements Certain matters discussed herein contain forward-looking statements. Any statements contained herein that are not statements of historical facts contained in this
Coherus Oncology has issued a cautionary statement regarding forward-looking statements in its latest annual report. The company recently completed the divestiture of its UDENYCA Business, marking a significant strategic shift away from biosimilars to concentrate on its immuno-oncology candidate, LOQTORZI. This transition is expected to focus on expanding LOQTORZI's sales and exploring new indications. The firm is also set to receive additional payments contingent on future net sales of UDENYCA, indicating potential for further revenue.
Read more →CHRS▼ -10.1%on this news
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Coherus Oncology presented new data on CHS-114 at the SITC meeting, highlighting its ability to selectively deplete CCR8+ Tregs and enhance CD8 T cell presence in tumors. The Phase 1b trial shows promising early antitumor activity, particularly in combination with toripalimab. The safety profile remains manageable, supporting further development of CHS-114 in advanced solid tumors.
Read more →About Coherus Oncology, Inc.
HeadquartersC/O DENNIS M. LANFEAR, REDWOOD CITY, CA, 94065
BIOPHARMAWATCH ELITE PLUS
Trade the next CHRS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime